Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients
Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.Peer-Reviewed Original Research